BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Džavík V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 2019;381:2032-42. [PMID: 31556978 DOI: 10.1056/NEJMoa1908419] [Cited by in Crossref: 329] [Cited by in F6Publishing: 59] [Article Influence: 164.5] [Reference Citation Analysis]
Number Citing Articles
1 Hirata TDC, Dagli-Hernandez C, Genvigir FDV, Lauschke VM, Zhou Y, Hirata MH, Hirata RDC. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. Mol Diagn Ther 2021. [PMID: 34357562 DOI: 10.1007/s40291-021-00549-z] [Reference Citation Analysis]
2 Kearney A, Linden K, Savage P, Menown IBA. Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials. Adv Ther 2021;38:2170-200. [PMID: 33844133 DOI: 10.1007/s12325-021-01711-z] [Reference Citation Analysis]
3 Yang H, Zhang F, Yang J, Zheng M, Cao R, Dai Y, Li C, Yao K, Qian J, Ge J; TARGET DAPT trial investigators. Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial. BMJ Open 2019;9:e033774. [PMID: 31852711 DOI: 10.1136/bmjopen-2019-033774] [Reference Citation Analysis]
4 Pordzik J, Eyileten-Postuła C, Jakubik D, Czajka P, Nowak A, De Rosa S, Gąsecka A, Cieślicka-Kapłon A, Sulikowski P, Filipiak KJ, Mirowska-Guzel D, Siller-Matula JM, Postuła M. MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. J Clin Med 2021;10:2371. [PMID: 34071189 DOI: 10.3390/jcm10112371] [Reference Citation Analysis]
5 Vogel B, Baber U, Cohen DJ, Sartori S, Sharma SK, Angiolillo DJ, Farhan S, Goel R, Zhang Z, Briguori C, Collier T, Dangas G, Dudek D, Escaned J, Gil R, Han YL, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta SR, Moliterno D, Ohman EM, Sardella G, Witzenbichler B, Gibson CM, Pocock S, Huber K, Mehran R. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol 2021. [PMID: 33991416 DOI: 10.1001/jamacardio.2021.1720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guedeney P, Collet JP. Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. J Clin Med 2020;9:E3474. [PMID: 33126578 DOI: 10.3390/jcm9113474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, Russell DA, Rocca B, Storey RF. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J 2021;42:2235-59. [PMID: 33764414 DOI: 10.1093/eurheartj/ehab128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Alasnag M, Jones TL, Hanfi Y, Ryan N. Sex-based outcomes in contemporary antiplatelet therapy trials. Open Heart 2021;8:e001761. [PMID: 34321335 DOI: 10.1136/openhrt-2021-001761] [Reference Citation Analysis]
9 Costa IBSDS, Andrade FTA, Carter D, Seleme VB, Costa MS, Campos CM, Hajjar LA. Challenges and Management of Acute Coronary Syndrome in Cancer Patients. Front Cardiovasc Med 2021;8:590016. [PMID: 34179121 DOI: 10.3389/fcvm.2021.590016] [Reference Citation Analysis]
10 Mehran R, Cao D, Baber U. Ticagrelor in Patients With Cancer: 2 Birds With 1 Stone. JACC CardioOncol 2020;2:251-3. [PMID: 34396234 DOI: 10.1016/j.jaccao.2020.05.002] [Reference Citation Analysis]
11 Takeji Y, Shiomi H, Morimoto T, Yoshikawa Y, Taniguchi R, Mutsumura-Nakano Y, Yamamoto K, Yamaji K, Tazaki J, Suwa S, Inoko M, Takeda T, Shirotani M, Ehara N, Ishii K, Inada T, Onodera T, Shinoda E, Yamamoto T, Tamura T, Nakatsuma K, Sakamoto H, Ando K, Soga Y, Furukawa Y, Sato Y, Nakagawa Y, Kadota K, Komiya T, Minatoya K, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 and the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators. Demographics, practice patterns and long-term outcomes of patients with non-ST-segment elevation acute coronary syndrome in the past two decades: the CREDO-Kyoto Cohort-2 and Cohort-3. BMJ Open 2021;11:e044329. [PMID: 33619198 DOI: 10.1136/bmjopen-2020-044329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. J Clin Med 2020;9:E2064. [PMID: 32630233 DOI: 10.3390/jcm9072064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
13 Johnson TW, Baos S, Collett L, Hutchinson JL, Nkau M, Molina M, Aungraheeta R, Reilly-Stitt C, Bowles R, Reeves BC, Rogers CA, Mundell SJ, Baumbach A, Mumford AD. Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial. J Am Heart Assoc 2020;9:e016495. [PMID: 33305660 DOI: 10.1161/JAHA.120.016495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Osman M, Farjo PD, Osman K, Radaideh Q, Munir MB, Kheiri B, Balla S. The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2020;49:184-91. [PMID: 31749123 DOI: 10.1007/s11239-019-01997-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Takeji Y, Shiomi H, Morimoto T, Yoshikawa Y, Taniguchi R, Mutsumura-Nakano Y, Yamamoto K, Yamaji K, Tazaki J, Kato ET, Watanabe H, Yamamoto E, Yamashita Y, Fuki M, Suwa S, Inoko M, Takeda T, Shirotani M, Ehara N, Ishii K, Inada T, Tamura T, Onodera T, Shinoda E, Yamamoto T, Watanabe H, Yaku H, Nakatsuma K, Sakamoto H, Ando K, Soga Y, Furukawa Y, Sato Y, Nakagawa Y, Kadota K, Komiya T, Minatoya K, Kimura T; CREDO-Kyoto AMI Registry Wave-1 and the CREDO-Kyoto AMI Registry Wave-2 Investigators. Changes in demographics, clinical practices and long-term outcomes of patients with ST segment-elevation myocardial infarction who underwent coronary revascularisation in the past two decades: cohort study. BMJ Open 2021;11:e043683. [PMID: 33789850 DOI: 10.1136/bmjopen-2020-043683] [Reference Citation Analysis]
16 Cao D, Dangas G, Mehran R. Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost. J Am Heart Assoc 2021;10:e019889. [PMID: 33559475 DOI: 10.1161/JAHA.120.019889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Ho MY, Chen PW, Feng WH, Su CH, Huang SW, Cheng CW, Yeh HI, Chen CP, Huang WC, Fang CC, Lin HW, Lin SH, Hsieh IC, Li YH. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. PLoS One 2021;16:e0251109. [PMID: 33979377 DOI: 10.1371/journal.pone.0251109] [Reference Citation Analysis]
18 Fontana P, Roffi M, Reny JL. Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. J Clin Med 2020;9:E194. [PMID: 31936845 DOI: 10.3390/jcm9010194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
19 Giallauria F, Di Lorenzo A, Venturini E, Pacileo M, D'Andrea A, Garofalo U, De Lucia F, Testa C, Cuomo G, Iannuzzo G, Gentile M, Nugara C, Sarullo FM, Marinus N, Hansen D, Vigorito C. Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation. J Clin Med 2021;10:1696. [PMID: 33920796 DOI: 10.3390/jcm10081696] [Reference Citation Analysis]
20 Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J 2020;228:1-7. [PMID: 32739652 DOI: 10.1016/j.ahj.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Hoogeveen RM, Hanssen NMJ, Brouwer JR, Mosterd A, Tack CJ, Kroon AA, de Borst GJ, Ten Berg J, van Trier T, van Lennep JR, Liem A, Serné E, Visseren FLJ, Cornel JH, Peters RJG, Jukema JW, Stroes ESG; PANORAMA working group. The challenge of choosing in cardiovascular risk management. Neth Heart J 2021. [PMID: 34259995 DOI: 10.1007/s12471-021-01599-y] [Reference Citation Analysis]
22 McClure JD, Ramsay JC, Berry C. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Heart Assoc 2020;9:e017109. [PMID: 32779497 DOI: 10.1161/JAHA.120.017109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
23 Gupta K, Khan A, Kumar M, Sawalha K, Abozenah M, Singhania R. Readmissions Rates After Myocardial Infarction for Gastrointestinal Bleeding: A National Perspective. Dig Dis Sci 2021;66:751-9. [PMID: 32436123 DOI: 10.1007/s10620-020-06315-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Goto S, Goto S. Is the answer to clinical questions provided by Bayesian network meta-analysis? Regarding the optimal duration of DAPT and the best subsequent SAPT. Eur Heart J Cardiovasc Pharmacother 2021;7:216-7. [PMID: 32424398 DOI: 10.1093/ehjcvp/pvaa032] [Reference Citation Analysis]
25 Shoji S, Sawano M, Sandhu AT, Heidenreich PA, Shiraishi Y, Ikemura N, Ueno K, Suzuki M, Numasawa Y, Fukuda K, Kohsaka S. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. JAMA Netw Open 2020;3:e202004. [PMID: 32239221 DOI: 10.1001/jamanetworkopen.2020.2004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
26 Verdoia M, Gioscia R, De Luca G. Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome. J Geriatr Cardiol 2021;18:210-8. [PMID: 33907551 DOI: 10.11909/j.issn.1671-5411.2021.03.010] [Reference Citation Analysis]
27 Kandzari DE, Kirtane AJ, Windecker S, Latib A, Kedhi E, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Choi JW, Caputo R, Kanitkar M, McLaurin B, Potluri S, Smith T, Spriggs D, Tolleson T, Nazif T, Parke M, Lee LC, Lung TH, Stone GW; Onyx ONE US/Japan Investigators. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv 2020;13:e009565. [PMID: 33167705 DOI: 10.1161/CIRCINTERVENTIONS.120.009565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
28 Xu Y, Shen Y, Chen D, Zhao P, Jiang J. Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis. J Interv Cardiol 2021;2021:9934535. [PMID: 34035674 DOI: 10.1155/2021/9934535] [Reference Citation Analysis]
29 Khan SU, Osman M, Khan MU, Khan MS, Zhao D, Mamas MA, Savji N, Al-Abdouh A, Hasan RK, Michos ED. Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Ann Intern Med 2020;172:474-83. [PMID: 32176890 DOI: 10.7326/M19-3763] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 15.0] [Reference Citation Analysis]
30 Chen C, Kan Y, Shi Z, Guo D, Fu W, Li Y, Lv Q, Li X, Si Y. Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis. Front Pharmacol 2020;11:608247. [PMID: 33732144 DOI: 10.3389/fphar.2020.608247] [Reference Citation Analysis]
31 Kim YH, Her AY, Kim BK, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Impact of preprocedural coronary flow grade on duration of dual antiplatelet therapy in acute myocardial infarction. Sci Rep 2021;11:11735. [PMID: 34083627 DOI: 10.1038/s41598-021-91130-5] [Reference Citation Analysis]
32 Cho JY, Lee SY, Yun KH, Kim BK, Hong SJ, Ko JS, Rhee SJ, Oh SK, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial. J Am Heart Assoc 2021;10:e019630. [PMID: 33739127 DOI: 10.1161/JAHA.120.019630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Chen PW, Feng WH, Ho MY, Su CH, Huang SW, Cheng CW, Yeh HI, Chen CP, Huang WC, Fang CC, Lin HLS, Hsieh IC, Li YH. P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. J Clin Med 2020;9:E1657. [PMID: 32492818 DOI: 10.3390/jcm9061657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wiebe J, Ndrepepa G, Kufner S, Lahmann AL, Xhepa E, Kuna C, Voll F, Gosetti R, Laugwitz KL, Joner M, Kastrati A, Cassese S. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e018304. [PMID: 33410332 DOI: 10.1161/JAHA.120.018304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Giri J, Nathan AS. The Pros and Cons of Percutaneous Coronary Intervention in Patients With Cancer. JACC CardioOncol 2019;1:156-8. [PMID: 34396176 DOI: 10.1016/j.jaccao.2019.11.002] [Reference Citation Analysis]
37 Kunkel KJ, Lemor A, Mahmood S, Villablanca P, Ramakrishna H. 2021 Update for the Diagnosis and Management of Acute Coronary Syndromes for the Perioperative Clinician. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00613-3. [PMID: 34400062 DOI: 10.1053/j.jvca.2021.07.032] [Reference Citation Analysis]
38 Ahmed N, Perek B. Severe complication of early cessation of therapy with ticagrelor after drug-eluting stent implantation. Kardiochir Torakochirurgia Pol 2021;18:119-20. [PMID: 34386056 DOI: 10.5114/kitp.2021.107476] [Reference Citation Analysis]
39 Luo L, Fu M, Li Y, Chen Z, Yu J, Luo J, Hu S, Tu L, Xu X. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention. Clin Cardiol 2020;43:235-41. [PMID: 31777973 DOI: 10.1002/clc.23305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Capodanno D, Angiolillo DJ. When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y12 Inhibition Induced by Ticagrelor. J Am Heart Assoc 2020;9:e019432. [PMID: 33302757 DOI: 10.1161/JAHA.120.019432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Linden K, Mailey J, Kearney A, Menown IBA. Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. Adv Ther 2020;37:2620-45. [PMID: 32361851 DOI: 10.1007/s12325-020-01355-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Kim DY, Cho SW, Park KT, Ahn JH, Park TK, Jang YH, Choi KH, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Lee SH, Hahn JY. Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients. J Korean Med Sci 2021;36:e106. [PMID: 33904262 DOI: 10.3346/jkms.2021.36.e106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Jin CD, Kim MH, Song K, Jin X, Lee KM, Park JS, Cho YR, Yun SC, Lee MS. Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial. J Clin Med 2021;10:2699. [PMID: 34207339 DOI: 10.3390/jcm10122699] [Reference Citation Analysis]
44 Bularga A, Meah MN, Doudesis D, Shah ASV, Mills NL, Newby DE, Lee KK. Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart 2021;8:e001707. [PMID: 34341097 DOI: 10.1136/openhrt-2021-001707] [Reference Citation Analysis]
45 Kubica J, Adamski P, Niezgoda P, Kubica A, Podhajski P, Barańska M, Umińska JM, Pietrzykowski Ł, Ostrowska M, Siller-Matula JM, Badarienė J, Bartuś S, Budaj A, Dobrzycki S, Fidor Ł, Gąsior M, Gessek J, Gierlotka M, Gil R, Gorący J, Grzelakowski P, Hajdukiewicz T, Jaguszewski M, Janion M, Kasprzak J, Kern A, Klecha A, Kleinrok A, Kochman W, Krakowiak B, Legutko J, Lesiak M, Nosal M, Piotrowski G, Przybylski A, Roleder T, Skonieczny G, Sobieszek G, Tycińska A, Wojciechowski D, Wojakowski W, Wójcik J, Zielińska M, Żurakowski A, Specchia G, Gorog DA, Navarese EP. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J 2021;28:607-14. [PMID: 34096012 DOI: 10.5603/CJ.a2021.0056] [Reference Citation Analysis]
46 Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, Stone GW, Kalra A, Bhatt DL. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation 2020;142:1425-36. [PMID: 32795096 DOI: 10.1161/CIRCULATIONAHA.120.046308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 27.0] [Reference Citation Analysis]
47 Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2020;9:E680. [PMID: 32138287 DOI: 10.3390/jcm9030680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
48 Capodanno D, Di Maio M, Greco A, Bhatt DL, Gibson CM, Goette A, Lopes RD, Mehran R, Vranckx P, Angiolillo DJ. Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2020;9:e017212. [PMID: 32805186 DOI: 10.1161/JAHA.120.017212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
49 Hromadka M, Motovska Z, Hlinomaz O, Kala P, Tousek F, Jarkovsky J, Beranova M, Jansky P, Svoboda M, Krepelkova I, Rokyta R, Widimsky P, Karpisek M. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. J Pers Med 2021;11:508. [PMID: 34199723 DOI: 10.3390/jpm11060508] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Chandiramani R, Cao D, Mehran R. Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess? Ann Transl Med 2020;8:556. [PMID: 32411779 DOI: 10.21037/atm.2020.01.28] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Toda Kato E, Goto S. The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb 2021;28:563-72. [PMID: 33853997 DOI: 10.5551/jat.RV17049] [Reference Citation Analysis]
52 Yun KH, Cho JY, Lee SY, Rhee SJ, Kim BK, Hong MK, Jang Y, Oh SK; TICO Investigators. Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial. Front Pharmacol 2020;11:620906. [PMID: 33519487 DOI: 10.3389/fphar.2020.620906] [Reference Citation Analysis]
53 Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM, Kim BK, Watanabe H, Song YB, Zhu Y, Vranckx P, Mehta S, Hong SJ, Ando K, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Jüni P, Mehran R. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 2021;373:n1332. [PMID: 34135011 DOI: 10.1136/bmj.n1332] [Reference Citation Analysis]
54 Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, van Geuns RJ, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol 2020;19:179. [PMID: 33066794 DOI: 10.1186/s12933-020-01153-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Yun KH, Lee SY, Cho BR, Jang WJ, Song YB, Oh JH, Chun WJ, Park YH, Im ES, Jeong JO, Oh SK, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC, Hahn JY; SMART‐CHOICE Investigators [Link]. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial. J Am Heart Assoc 2021;10:e018366. [PMID: 33345567 DOI: 10.1161/JAHA.120.018366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Feng WH, Hsieh IC, Li YH. P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin? Acta Cardiol Sin 2021;37:1-8. [PMID: 33488022 DOI: 10.6515/ACS.202101_37(1).20200806A] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Liang XY, Li Y, Qiao X, Zhang WJ, Wang ZL. Clinical Outcomes of Very Short Term Dual Antiplatelet Therapy in Patients With or Without Diabetes Undergoing Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Cardiovasc Med 2021;8:655718. [PMID: 34277725 DOI: 10.3389/fcvm.2021.655718] [Reference Citation Analysis]
58 Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y; TICO Investigators. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020;323:2407-16. [PMID: 32543684 DOI: 10.1001/jama.2020.7580] [Cited by in Crossref: 98] [Cited by in F6Publishing: 70] [Article Influence: 98.0] [Reference Citation Analysis]
59 Gelbenegger G, Schoergenhofer C, Jilma B, Gager GM, Dizdarevic AM, Mamas MA, Parapid B, Velagapudi P, Siller-Matula JM. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Clin Pharmacol Ther 2021;110:424-31. [PMID: 33668076 DOI: 10.1002/cpt.2226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]